Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs)

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,749	184 Pages	360iResearch	January, 2024	IRE18437789

Best Price Guarantee
Price	from $4,749
Length	184 Pages
Publisher	360iResearch
Published Date	January, 2024
SKU	IRE18437789

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030

The Cystic Fibrosis Market size was estimated at USD 5.88 billion in 2023 and expected to reach USD 6.44 billion in 2024, at a CAGR 9.53% to reach USD 11.13 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cystic Fibrosis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cystic Fibrosis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cystic Fibrosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcresta Therapeutics, Inc., AlgiPharma AS, AstraZeneca PLC, CHIESI Farmaceutici S.p.A., Elucigene Diagnostics by Delta Diagnostics (UK) Limited, F. Hoffmann-La Roche AG, Galapagos NV, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., NovaBiotics Ltd., Novartis AG, Pharmaxis Ltd., PTC Therapeutics, Inc., and Vertex Pharmaceuticals Incorporated.

Market Segmentation & Coverage

This research report categorizes the Cystic Fibrosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
Bronchodilators
CFTR Modulators
Mucolytics
Pancreatic Enzyme Supplements
Route of Administration
Inhaled Drugs
Oral Drugs
Region
Americas
Argentina

Brazil

Canada

Mexico

United States
California

Florida

Illinois

New York

Ohio

Pennsylvania

Texas
Asia-Pacific
Australia

China

India

Indonesia

Japan

Malaysia

Philippines

Singapore

South Korea

Taiwan

Thailand

Vietnam
Europe, Middle East & Africa
Denmark

Egypt

Finland

France

Germany

Israel

Italy

Netherlands

Nigeria

Norway

Poland

Qatar

Russia

Saudi Arabia

South Africa

Spain

Sweden

Switzerland

Turkey

United Arab Emirates

United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cystic Fibrosis Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cystic Fibrosis Market?
3. What are the technology trends and regulatory frameworks in the Cystic Fibrosis Market?
4. What is the market share of the leading vendors in the Cystic Fibrosis Market?
5. Which modes and strategic moves are suitable for entering the Cystic Fibrosis Market?

Note: PDF & Excel + Online Access - 1 Year

1. Preface: 1.1. Objectives of the Study; 1.2. Market Segmentation & Coverage; 1.3. Years Considered for the Study; 1.4. Currency & Pricing; 1.5. Language; 1.6. Limitations; 1.7. Assumptions; 1.8. Stakeholders
2. Research Methodology: 2.1. Define: Research Objective; 2.2. Determine: Research Design; 2.3. Prepare: Research Instrument; 2.4. Collect: Data Source; 2.5. Analyze: Data Interpretation; 2.6. Formulate: Data Verification; 2.7. Publish: Research Report; 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview: 4.1. Introduction; 4.2. Cystic Fibrosis Market, by Region
5. Market Insights: 5.1. Market Dynamics; 5.1.1. Drivers; 5.1.1.1. Rising prevalence of Cystic Fibrosis & improved diagnostic technologies; 5.1.1.2. Increasing global awareness for Cystic Fibrosis; 5.1.1.3. Favorable initiatives are taken by NGOs, government, and private companies; 5.1.2. Restraints; 5.1.2.1. Expiring patents and generic drugs; 5.1.2.2. Increase in genetic mutation rate; 5.1.3. Opportunities; 5.1.3.1. Research & development activities and robust drug development pipeline; 5.1.3.2. Growing strategic collaborations, merger, and acquisition; 5.1.4. Challenges; 5.1.4.1. High cost involved in treatment and complicated pathophysiology; 5.2. Market Segmentation Analysis; 5.3. Market Trend Analysis; 5.4. Cumulative Impact of High Inflation; 5.5. Porter’s Five Forces Analysis; 5.5.1. Threat of New Entrants; 5.5.2. Threat of Substitutes; 5.5.3. Bargaining Power of Customers; 5.5.4. Bargaining Power of Suppliers; 5.5.5. Industry Rivalry; 5.6. Value Chain & Critical Path Analysis; 5.7. Regulatory Framework
6. Cystic Fibrosis Market, by Drug Class: 6.1. Introduction; 6.2. Bronchodilators; 6.3. CFTR Modulators; 6.4. Mucolytics; 6.5. Pancreatic Enzyme Supplements
7. Cystic Fibrosis Market, by Route of Administration: 7.1. Introduction; 7.2. Inhaled Drugs; 7.3. Oral Drugs
8. Americas Cystic Fibrosis Market: 8.1. Introduction; 8.2. Argentina; 8.3. Brazil; 8.4. Canada; 8.5. Mexico; 8.6. United States
9. Asia-Pacific Cystic Fibrosis Market: 9.1. Introduction; 9.2. Australia; 9.3. China; 9.4. India; 9.5. Indonesia; 9.6. Japan; 9.7. Malaysia; 9.8. Philippines; 9.9. Singapore; 9.10. South Korea; 9.11. Taiwan; 9.12. Thailand; 9.13. Vietnam
10. Europe, Middle East & Africa Cystic Fibrosis Market: 10.1. Introduction; 10.2. Denmark; 10.3. Egypt; 10.4. Finland; 10.5. France; 10.6. Germany; 10.7. Israel; 10.8. Italy; 10.9. Netherlands; 10.10. Nigeria; 10.11. Norway; 10.12. Poland; 10.13. Qatar; 10.14. Russia; 10.15. Saudi Arabia; 10.16. South Africa; 10.17. Spain; 10.18. Sweden; 10.19. Switzerland; 10.20. Turkey; 10.21. United Arab Emirates; 10.22. United Kingdom
11. Competitive Landscape: 11.1. FPNV Positioning Matrix; 11.2. Market Share Analysis, By Key Player; 11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio: 12.1. Key Company Profiles; 12.1.1. AbbVie Inc.; 12.1.2. Alcresta Therapeutics, Inc.; 12.1.3. AlgiPharma AS; 12.1.4. AstraZeneca PLC; 12.1.5. CHIESI Farmaceutici S.p.A.; 12.1.6. Elucigene Diagnostics by Delta Diagnostics (UK) Limited; 12.1.7. F. Hoffmann-La Roche AG; 12.1.8. Galapagos NV; 12.1.9. Gilead Sciences, Inc.; 12.1.10. Johnson & Johnson Services, Inc.; 12.1.11. NovaBiotics Ltd.; 12.1.12. Novartis AG; 12.1.13. Pharmaxis Ltd.; 12.1.14. PTC Therapeutics, Inc.; 12.1.15. Vertex Pharmaceuticals Incorporated; 12.2. Key Product Portfolio
13. Appendix: 13.1. Discussion Guide; 13.2. License & Pricing; FIGURE 1. CYSTIC FIBROSIS MARKET RESEARCH PROCESS; FIGURE 2. CYSTIC FIBROSIS MARKET SIZE, 2023 VS 2030; FIGURE 3. CYSTIC FIBROSIS MARKET SIZE, 2018-2030 (USD MILLION); FIGURE 4. CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2030 (%); FIGURE 5. CYSTIC FIBROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 6. CYSTIC FIBROSIS MARKET DYNAMICS; FIGURE 7. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%); FIGURE 8. CYSTIC FIBROSIS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 9. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%); FIGURE 10. CYSTIC FIBROSIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 11. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 12. AMERICAS CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 13. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%); FIGURE 14. UNITED STATES CYSTIC FIBROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 15. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 16. ASIA-PACIFIC CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%); FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CYSTIC FIBROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION); FIGURE 19. CYSTIC FIBROSIS MARKET, FPNV POSITIONING MATRIX, 2023; FIGURE 20. CYSTIC FIBROSIS MARKET SHARE, BY KEY PLAYER, 2023

Cystic Fibrosis Therapeutics Market Report by Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement , and Others), Route of Administration (Oral Drugs, and Inhaled Drugs), Distribution Channel (Hospitals, Retail Pharmacies, and Others), Regions and Company Analysis 2024-2032

June, 2024 | Published by: Renub Research | USD $2,790
Cystic Fibrosis Therapeutics Market Report by Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators, Antibiotics, and Others), Drug Molecule Type (Small Molecule Drugs, Biologics), Route of Administration (Oral Drugs, Inhaled Drugs), End-User (Hospitals, Clinics, and Others), and Region 2024-2032

July, 2024 | Published by: IMARC Services Pvt. Ltd. | USD $3,899
Cystic Fibrosis Therapeutics Market Size, Trends, Analysis, and Outlook By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration (Oral Drugs, Inhaled Drugs), by Region, Country, Segment, and Companies, 2024-2030

March, 2024 | Published by: VPA Research | USD $3,980
Cystic Fibrosis Market Forecasts to 2030 – Global Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, Antibiotics and Other Drug Classes), Treatment Method (Medication and Devices), Route of Administration (Oral and Inhaled), Distribution Channel and By Geography

November, 2023 | Published by: Stratistics Market Research Consulting | USD $4,150
Cystic Fibrosis Market Share, Size, Trends, Industry Analysis Report, By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements), Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

August, 2022 | Published by: Polaris Market Research & Consulting LLP | USD $4,250
Global Cystic Fibrosis (CF) Lung Disease Market (2024 Edition): Analysis By Drug Type (CFTR Modulators, Bronchodilators, Mucolytics, Anti-infectives), Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

January, 2024 | Published by: Azoth Analytics | USD $2,450

PDF E-mail From Publisher:	$4,749
PDF E-mail From Publisher (2-5)Users License:	$5,749
Site License:	$6,749
Global Site License Fulfilled by Publisher:	$8,749

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030

Research Assistance

Other tasks

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030

Cystic Fibrosis Market by Drug Class (Bronchodilators, CFTR Modulators, Mucolytics), Route of Administration (Inhaled Drugs, Oral Drugs) - Global Forecast 2024-2030

Cystic Fibrosis Therapeutics Market Size, Trends, Analysis, and Outlook By Drug Class (Pancreatic Enzyme Supplements, Mucolytics, Bronchodilators, CFTR Modulators), By Route of Administration (Oral Drugs, Inhaled Drugs), by Region, Country, Segment, and Companies, 2024-2030

Cystic Fibrosis Market Forecasts to 2030 – Global Analysis By Drug Class (Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, Antibiotics and Other Drug Classes), Treatment Method (Medication and Devices), Route of Administration (Oral and Inhaled), Distribution Channel and By Geography

Cystic Fibrosis Market Share, Size, Trends, Industry Analysis Report, By Drug Class (CFTR Modulators, Mucolytics, Bronchodilators, Pancreatic Enzyme Supplements), Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030

Global Cystic Fibrosis (CF) Lung Disease Market (2024 Edition): Analysis By Drug Type (CFTR Modulators, Bronchodilators, Mucolytics, Anti-infectives), Route of Administration, Distribution Channel, By Region, By Country: Market Insights and Forecast (2019-2029)

Research Assistance

Other tasks